List of Studies ( Metabolite:N-hydroxyisoleucine)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST002010 | AN003276 | Chemoresistant Ovarian Cancer Global Metabolomics | Cultured cells | Human | Cancer | The University of South Australia | Intensity |
ST002066 | AN003365 | Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer | Lung | Mouse | Cancer | The Walter and Eliza Hall Institute of Medical Research | peak height |
ST002104 | AN003439 | Chemoresistant Cancer Cell Lines are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations | Cultured cells | Human | Cancer | Future Industries Institute | peak height |
ST002412 | AN003931 | Metabolic effects of the protein kinase R | Macrophages | Mouse | Hudson | peak height | |
ST002698 | AN004372 | Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites | Infected Red Blood Cells | Plasmodium berghei | Malaria | Peter Doherty Institute for Infection and Immunity | peak height |
ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Bacteria | Monash Institute of Pharmaceutical Sciences | peak height | |
ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
ST000403 | AN000643 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000414 | AN000655 | Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action | Cells | Plasmodium falciparum | Malaria | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height |
ST000539 | AN000819 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST003160 | AN005184 | New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | Peak height |
ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001547 | AN002576 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | Peak intensity | |
ST001547 | AN002577 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | Peak intensity | |
ST001548 | AN002578 | β-Adrenergic regulation of metabolism in macrophages (part-II) | Macrophages | Human | Monash University | Peak intensity | |
ST001548 | AN002579 | β-Adrenergic regulation of metabolism in macrophages (part-II) | Macrophages | Human | Monash University | Peak intensity | |
ST001549 | AN002580 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | Peak intensity | |
ST001549 | AN002581 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | Peak intensity | |
ST002108 | AN003448 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST002309 | AN003771 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
ST001175 | AN001950 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |
ST001315 | AN002189 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |